This is “bigger” than the ChatGPT moment, Lieberman wrote to me. “But Pandora’s Box hasn’t been opened for the rest of the ...

2026 is highlighted as the year of the singularity with Elon Musk warning of underestimated impacts; conversations with him ...

For quantum computers to outperform their classical counterparts, they need more quantum bits, or qubits. State-of-the-art ...

AI models are getting so good at finding vulnerabilities that some experts say the tech industry might need to rethink how ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

“I was curious to establish a baseline for when LLMs are effectively able to solve open math problems compared to where they ...

There are hundreds of cell types in the human body, each with a specific role spelled out in their DNA. In theory, all it ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Trust in science needs researchers, journals and institutions to correct the scientific record quickly and transparently when ...

Inside Michigan Tech's Aging, Cognition and Action Lab, space debris rains down on a screen as players scramble to deflect it ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...